Company Filing History:
Years Active: 2018
Title: Chang Kai Soh: Innovator in Hydroxamate Derivatives
Introduction
Chang Kai Soh is a notable inventor based in Singapore, recognized for his contributions to the field of medicinal chemistry. He has developed innovative compounds that have potential therapeutic applications, particularly in the treatment of diseases associated with histone deacetylase and kinase activities.
Latest Patents
Chang Kai Soh holds a patent for "Fused pyrimidine-based hydroxamate derivatives." This invention relates to fused pyrimidine-based hydroxamate compounds that act as inhibitors of histone deacetylase (HDAC) and kinases. The patent details hydroxamate substituted purine or 5H-pyrrolo[3,2-d]pyrimidine derivatives, methods for their preparation, and pharmaceutical compositions containing these compounds. These compounds are intended for use in treating disorders related to enzymes with HDAC, non-HDAC, and kinase functions.
Career Highlights
Chang Kai Soh is affiliated with the Agency for Science, Technology and Research, where he continues to advance his research in the field of biochemistry and pharmacology. His work has significant implications for developing new therapeutic strategies.
Collaborations
He collaborates with esteemed colleagues, including Haishan Wang and DiZhong Chen, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Chang Kai Soh's work in developing hydroxamate derivatives showcases his commitment to advancing medical science. His contributions are paving the way for new treatments that could benefit many patients in the future.